Context Therapeutics (NASDAQ:CNTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Context Therapeutics (NASDAQ:CNTX) from a sell rating to a hold rating in a report released on Monday.

Other research analysts also recently issued reports about the company. D. Boral Capital restated a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research note on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, January 21st. HC Wainwright upped their price target on shares of Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Finally, JonesTrading assumed coverage on shares of Context Therapeutics in a research report on Monday, December 22nd. They issued a “buy” rating and a $7.00 price objective on the stock. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Context Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $6.00.

Context Therapeutics Stock Down 0.4%

Shares of CNTX stock opened at $2.32 on Monday. The company has a market cap of $213.16 million, a P/E ratio of -9.67 and a beta of 1.94. The business has a 50 day moving average of $1.73 and a two-hundred day moving average of $1.27. Context Therapeutics has a 52 week low of $0.49 and a 52 week high of $2.85.

Institutional Trading of Context Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Quadrature Capital Ltd bought a new position in shares of Context Therapeutics in the fourth quarter valued at approximately $68,000. Clear Harbor Asset Management LLC lifted its position in Context Therapeutics by 60.5% in the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock worth $90,000 after purchasing an additional 35,000 shares during the period. Citadel Advisors LLC bought a new position in Context Therapeutics during the 3rd quarter valued at $100,000. XTX Topco Ltd increased its position in shares of Context Therapeutics by 858.8% during the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after purchasing an additional 91,008 shares during the period. Finally, State Street Corp increased its position in shares of Context Therapeutics by 8.5% during the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock valued at $243,000 after purchasing an additional 13,000 shares during the period. 14.03% of the stock is owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.